Sigma Planning Corp Reduces Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Sigma Planning Corp reduced its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 57.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,583 shares of the medical equipment provider’s stock after selling 6,198 shares during the quarter. Sigma Planning Corp’s holdings in Intuitive Surgical were worth $1,546,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. WCM Investment Management LLC bought a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $575,536,000. International Assets Investment Management LLC grew its holdings in shares of Intuitive Surgical by 32,360.5% during the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after purchasing an additional 684,749 shares during the last quarter. Alphinity Investment Management Pty Ltd grew its holdings in shares of Intuitive Surgical by 113.2% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after purchasing an additional 677,455 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new position in shares of Intuitive Surgical during the third quarter valued at approximately $178,667,000. Finally, Quadrature Capital Ltd grew its holdings in shares of Intuitive Surgical by 466.2% during the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock valued at $99,601,000 after purchasing an additional 280,480 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Price Performance

ISRG opened at $368.93 on Tuesday. The company has a market capitalization of $130.77 billion, a price-to-earnings ratio of 66.59, a price-to-earnings-growth ratio of 5.69 and a beta of 1.36. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76. The business has a 50 day moving average price of $386.57 and a two-hundred day moving average price of $344.41.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same period in the prior year, the firm posted $1.00 earnings per share. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. Equities analysts expect that Intuitive Surgical, Inc. will post 4.93 EPS for the current fiscal year.

Insider Activity

In other news, SVP Mark Brosius sold 196 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares in the company, valued at approximately $736,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Fredrik Widman sold 5,041 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the sale, the vice president now directly owns 110 shares in the company, valued at $43,677.70. The disclosure for this sale can be found here. In the last 90 days, insiders sold 248,418 shares of company stock worth $95,927,097. Insiders own 0.80% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on ISRG. Stifel Nicolaus upped their target price on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. BTIG Research boosted their price objective on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday. Mizuho boosted their price objective on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research report on Thursday, January 25th. Citigroup boosted their price objective on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, StockNews.com downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.